Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Genetic Analysis AS's enterprise value is €2.62 Mil.
Genetic Analysis AS's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.44 Mil. Therefore, Genetic Analysis AS's EV-to-EBITDA for today is -5.91.
The historical rank and industry rank for Genetic Analysis AS's EV-to-EBITDA or its related term are showing as below:
FRA:8V8'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -15.38 Med: -2.11 Max: -0.33
Current: -5.58
During the past 7 years, the highest EV-to-EBITDA of Genetic Analysis AS was -0.33. The lowest was -15.38. And the median was -2.11.
FRA:8V8's EV-to-EBITDA is ranked worse than 100% of 119
companies
in the Medical Diagnostics & Research industry
Industry Median: 16.29
vs FRA:8V8: -5.58
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Genetic Analysis AS (FRA:8V8) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Genetic Analysis AS's PE Ratio (TTM) for today is calculated as:
Genetic Analysis AS's share price for today is €0.0408.
Genetic Analysis AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.014.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Genetic Analysis AS's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8V8 vs TMO, DHR, IDXX: EV-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Genetic Analysis AS's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetic Analysis AS EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Analysis AS's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Genetic Analysis AS's EV-to-EBITDA falls into.
Genetic Analysis AS's current Enterprise Value is €2.62 Mil.
Genetic Analysis AS's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.44 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genetic Analysis AS (FRA:8V8) has a EV-to-EBITDA of -5.91 as of Aug. 29, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Genetic Analysis AS. According to the industry distribution chart, Genetic Analysis AS ranks #999999 out of 119 companies in the Medical Diagnostics & Research industry.
Is Genetic Analysis AS's EV-to-EBITDA too high?
Genetic Analysis AS's current EV-to-EBITDA is -5.91. Based on the distribution chart, Genetic Analysis AS ranks #999999 out of 119 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Genetic Analysis AS has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Genetic Analysis AS's EV-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genetic Analysis AS ranks #999999 out of 119 companies for EV-to-EBITDA. This places Genetic Analysis AS in the lower half of its industry. The industry median EV-to-EBITDA is 16.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 16.29, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Genetic Analysis AS. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 16.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genetic Analysis AS's current EV-to-EBITDA is -5.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Analysis AS stock overvalued right now?
Genetic Analysis AS (FRA:8V8) has a current EV-to-EBITDA of -5.91. The stock's GF Value™ is €0.04, compared to a current price of €0.04 — trading 2% above its estimated fair value. The current EV-to-EBITDA is -5.91. Genetic Analysis AS's overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Genetic Analysis AS (FRA:8V8), the current EV-to-EBITDA is -5.91 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genetic Analysis AS (FRA:8V8) Overvalued in 2026?
Based on GuruFocus' analysis, Genetic Analysis AS stock appears to be overvalued.
The current stock price of €0.04 is trading 2% above its estimated GF Value™ of €0.04.
Key valuation signals for FRA:8V8:
EV-to-EBITDA: -5.91
GF Value™: €0.04 vs. price of €0.04 (2% above fair value)
No single metric tells the full story. See the FRA:8V8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genetic Analysis AS is a research-driven diagnostic company dedicated to delivering diagnostic solutions to the growing human microbiota market. It is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients. Geographically, it operates in the USA, Europe, and the Rest of the world. Geographically, the company sells products in the USA, Europe, and the rest of the world. The majority of its revenue is generated from the USA. The GA-map technology platform and product portfolio are currently used across three main market segments: Clinical diagnostics, research (academic and industry), and Consumer Health.
34GF Score
Get the complete analysis for FRA:8V8
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8V8 has been successfully added to your 
